OncoMed Pharmaceuticals initiates breast cancer study with vantictumab

|About: OncoMed Pharmaceuticals, Inc (OMED)|By:, SA News Editor

OncoMed Pharmaceuticals (OMED) starts a Phase 1b dose escalation trial for vantictumab (with paclitaxel) in patients with first-, second- and third-line, locally advanced or metastatic HER2 negative breast cancer.

OMED intends to initiate three Phase 1 trials of vantictumab this year. (PR)

The company is developing the drug with Bayer (BAYZF).